Skip to main content

02-03-2017 | ANCA-associated vasculitis | Review | Article

Rituximab in ANCA-Associated Vasculitis

Current Rheumatology Reports

Authors: Romina I. Hassan, Angelo L. Gaffo

Publisher: Springer US


Purpose of Review

The purpose of this review is to describe the efficacy and safety of rituximab (RTX) as a remission induction and maintenance therapy in ANCA-associated vasculitis (AAV).

Recent Findings

A PubMed search was carried out to track down articles published between February 2006 and February 2016. Randomized controlled trials (RCTs) that encompassed patients with AAV were included. The American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) 2014–2015 online abstracts were also reviewed whether they were RTCs or not. Ten PubMed RCTs were analyzed along with eight ACR and four EULAR abstracts. RTX was not inferior to cyclophosphamide (CYC) for remission induction in AAV; it was superior to CYC in patients with relapsing disease and superior for remission maintenance in comparison with azathioprine (AZA).


Rituximab is a therapeutic option to induce and maintain remission in patients with AAV.

Please log in to get access to this content

Related topics

Have your say on Medicine Matters

Visit the conference hub

Image Credits